Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2521 to 2535 of 8215 results

  1. Familial Breast Cancer: initial assessment and genetic testing (update)

    In development Reference number: GID-NG10438 Expected publication date:  22 April 2027

    NICE guideline
    In development

  2. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-IPG10448 Expected publication date: TBC

    Interventional procedures guidance
    In development

  3. In-situ normothermic regional perfusion of the abdomen for donor livers following circulatory death

    In development Reference number: GID-IPG10405 Expected publication date: TBC

    Interventional procedures guidance
    In development

  4. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]

    In development Reference number: GID-TA11414 Expected publication date:  10 June 2026

    Technology appraisal guidance
    In development

  5. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356

    In development Reference number: GID-TA11416 Expected publication date:  08 July 2026

    Technology appraisal guidance
    In development

  6. Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over ID6448

    In development Reference number: GID-TA11564 Expected publication date:  08 July 2026

    Technology appraisal guidance
    In development

  7. Semaglutide for treating moderate to advanced liver fibrosis (without cirrhosis) caused by metabolic dysfunction-associated steatohepatitis [ID6458]

    In development Reference number: GID-TA11477 Expected publication date:  12 August 2026

    Technology appraisal guidance
    In development

  8. Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379

    In development Reference number: GID-TA11429 Expected publication date:  09 September 2026

    Technology appraisal guidance
    In development

  9. Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446

    In development Reference number: GID-TA11552 Expected publication date:  09 September 2026

    Technology appraisal guidance
    In development

  10. Depemokimab for treating severe eosinophilic asthma in people 12 years and over [ID6447]

    In development Reference number: GID-TA11553 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]

    In development Reference number: GID-TA11334 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Severe and enduring mental illness guidance review

    In development Reference number: GID-NG10465 Expected publication date: TBC

    NICE guideline
    In development

  13. Head injury (QS74) update

    In development Reference number: GID-QS10189 Expected publication date:  07 January 2027

    Quality standard
    In development

  14. Aggressive behaviour in people receiving NHS or social care

    In development Reference number: GID-QS10196 Expected publication date:  28 January 2027

    Quality standard
    In development

  15. Suspected Cancer: recognition and referral (update)

    In development Reference number: GID-NG10443 Expected publication date:  25 March 2026

    NICE guideline
    In development